Trial Profile
Randomized Study of Docetaxel Versus Docetaxel Plus Genasense (G3139; Bcl-2 Antisense Oligonucleotide) [oblimersen] in Patients With Previously Treated Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oblimersen (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Sep 2005 New trial record.